Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Leukemia Therapeutic Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Induction Therapy
  • 1.4.3 Consolidation Therapy
  • 1.4.4 Maintenance Therapy
• 1.5 Market by Application
  • 1.5.1 Global Leukemia Therapeutic Market Share by Application (2014-2025)
  • 1.5.2 Cancer Research Centers
  • 1.5.3 Diagnostic Laboratories
  • 1.5.4 Clinics
  • 1.5.5 Hospitals
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Leukemia Therapeutic Market Size
• 2.2 Leukemia Therapeutic Growth Trends by Regions
  • 2.2.1 Leukemia Therapeutic Market Size by Regions (2014-2025)
  • 2.2.2 Leukemia Therapeutic Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Leukemia Therapeutic Market Size by Manufacturers
  • 3.1.1 Global Leukemia Therapeutic Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Leukemia Therapeutic Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Leukemia Therapeutic Market Concentration Ratio (CR5 and HHI)
• 3.2 Leukemia Therapeutic Key Players Head office and Area Served
• 3.3 Key Players Leukemia Therapeutic Product/Solution/Service
• 3.4 Date of Enter into Leukemia Therapeutic Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Leukemia Therapeutic Market Size by Type (2014-2019)
• 4.2 Global Leukemia Therapeutic Market Size by Application (2014-2019)

5 United States

• 5.1 United States Leukemia Therapeutic Market Size (2014-2019)
• 5.2 Leukemia Therapeutic Key Players in United States
• 5.3 United States Leukemia Therapeutic Market Size by Type
• 5.4 United States Leukemia Therapeutic Market Size by Application

6 Europe

• 6.1 Europe Leukemia Therapeutic Market Size (2014-2019)
• 6.2 Leukemia Therapeutic Key Players in Europe
• 6.3 Europe Leukemia Therapeutic Market Size by Type
• 6.4 Europe Leukemia Therapeutic Market Size by Application

7 China

• 7.1 China Leukemia Therapeutic Market Size (2014-2019)
• 7.2 Leukemia Therapeutic Key Players in China
• 7.3 China Leukemia Therapeutic Market Size by Type
• 7.4 China Leukemia Therapeutic Market Size by Application

8 Japan

• 8.1 Japan Leukemia Therapeutic Market Size (2014-2019)
• 8.2 Leukemia Therapeutic Key Players in Japan
• 8.3 Japan Leukemia Therapeutic Market Size by Type
• 8.4 Japan Leukemia Therapeutic Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Leukemia Therapeutic Market Size (2014-2019)
• 9.2 Leukemia Therapeutic Key Players in Southeast Asia
• 9.3 Southeast Asia Leukemia Therapeutic Market Size by Type
• 9.4 Southeast Asia Leukemia Therapeutic Market Size by Application

10 India

• 10.1 India Leukemia Therapeutic Market Size (2014-2019)
• 10.2 Leukemia Therapeutic Key Players in India
• 10.3 India Leukemia Therapeutic Market Size by Type
• 10.4 India Leukemia Therapeutic Market Size by Application

11 Central & South America

• 11.1 Central & South America Leukemia Therapeutic Market Size (2014-2019)
• 11.2 Leukemia Therapeutic Key Players in Central & South America
• 11.3 Central & South America Leukemia Therapeutic Market Size by Type
• 11.4 Central & South America Leukemia Therapeutic Market Size by Application

12 International Players Profiles

• 12.1 Genzyme
  • 12.1.1 Genzyme Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Leukemia Therapeutic Introduction
  • 12.1.4 Genzyme Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.1.5 Genzyme Recent Development
• 12.2 Novartis International
  • 12.2.1 Novartis International Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Leukemia Therapeutic Introduction
  • 12.2.4 Novartis International Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.2.5 Novartis International Recent Development
• 12.3 Pfizer
  • 12.3.1 Pfizer Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Leukemia Therapeutic Introduction
  • 12.3.4 Pfizer Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.3.5 Pfizer Recent Development
• 12.4 Roche Holding
  • 12.4.1 Roche Holding Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Leukemia Therapeutic Introduction
  • 12.4.4 Roche Holding Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.4.5 Roche Holding Recent Development
• 12.5 Celgene Corporation
  • 12.5.1 Celgene Corporation Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Leukemia Therapeutic Introduction
  • 12.5.4 Celgene Corporation Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.5.5 Celgene Corporation Recent Development
• 12.6 Ariad Pharmaceuticals
  • 12.6.1 Ariad Pharmaceuticals Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Leukemia Therapeutic Introduction
  • 12.6.4 Ariad Pharmaceuticals Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.6.5 Ariad Pharmaceuticals Recent Development
• 12.7 Clavis Pharma
  • 12.7.1 Clavis Pharma Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Leukemia Therapeutic Introduction
  • 12.7.4 Clavis Pharma Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.7.5 Clavis Pharma Recent Development
• 12.8 Sunesis Pharmaceuticals
  • 12.8.1 Sunesis Pharmaceuticals Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Leukemia Therapeutic Introduction
  • 12.8.4 Sunesis Pharmaceuticals Revenue in Leukemia Therapeutic Business (2014-2019)
  • 12.8.5 Sunesis Pharmaceuticals Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Leukemia is a type of cancer which is formed in blood tissues. Leukemia occurs in bone marrow which is a soft tissue. Leukemia develops by the uncontrolled growth of blood cells in the bone marrow. Leukemia is also defined as a cancer of white blood cells. Leukemia therapeutics consists of three steps including induction therapy, consolidation therapy and maintenance therapy.
In recent time there is increased use of leukemia therapeutic due to rising number of cancer diseases across the world. Rising aging population, lifestyle factors and increasing awareness for healthcare are some of the key driving factors for the growth of the global leukemia therapeutics market. In addition, innovative and targeted drug delivery is also fuelling the growth of the global leukemia therapeutics market. However, availability of large numbers of generic form of drugs and limited treatment options are some of the major factors restraining the growth of the global leukemia therapeutics market. In addition, high unmet need for diagnosis is also restraining the growth of the global leukemia therapeutics market.
North America followed by Europe dominates the global leukemia therapeutics market due to rising incidence of cancer and growing aging population. Asia is expected to show high growth rate due to rising incidence of cancer. China and India are expected to be the fastest growing leukemia markets in Asia region. Some of the key driving forces for the leukemia therapeutic market in emerging countries are increasing R&D investment, large pool of patients and rising government funding.
In 2018, the global Leukemia Therapeutic market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Leukemia Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Leukemia Therapeutic development in United States, Europe and China.

The key players covered in this study
Genzyme
Novartis International
Pfizer
Roche Holding
Celgene Corporation
Ariad Pharmaceuticals
Clavis Pharma
Sunesis Pharmaceuticals

Market segment by Type, the product can be split into
Induction Therapy
Consolidation Therapy
Maintenance Therapy

Market segment by Application, split into
Cancer Research Centers
Diagnostic Laboratories
Clinics
Hospitals

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Leukemia Therapeutic status, future forecast, growth opportunity, key market and key players.
To present the Leukemia Therapeutic development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Leukemia Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.